Role of Prohepcidin in Uremic Patients

Haseki Training and Research Hospital25 enrolled

Overview

The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Inflammation Chronic Kidney Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * hemodialysis and peritoneal dialysis patients who had been on dialysis therapy for more than 3 months, * age between 18-80 years, * patients with creatinine clearance between 15-30 ml/min. Exclusion Criteria: * age less than 18 or more than 80, * diabetic patients, * current active infectious or inflammatory disease.

Locations (1)

Haseki Training and Research Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

prohepcidin level

Prohepcidin levels will be compared with other inflammatory markers.

Time frame: Six months

Secondary Outcomes

Anemia and inflammatory markers

Correlations of prohepcidin levels with anemia and inflamatory markers

Time frame: Six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.